Orme Sophie E, Moncrieff Marc D
Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich NR4 7UY, UK.
Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK.
Cancers (Basel). 2024 Feb 23;16(5):895. doi: 10.3390/cancers16050895.
Surgical wide local excision (WLE) remains the current standard of care for primary cutaneous melanoma. WLE is an elective procedure that aims to achieve locoregional disease control with minimal functional and cosmetic impairment. Despite several prospective randomised trials, the optimal extent of excision margin remains controversial, and this is reflected in the persistent lack of consensus in guidelines globally. Furthermore, there is now the added difficulty of interpreting existing trial data in the context of the evolving role of surgery in the management of melanoma, with our increased understanding of clinicopathologic and genomic prognostic markers leading to the often routine use of sentinel node biopsy (SNB) as a staging procedure, in addition to the development of adjuvant systemic therapies for high-risk disease. An ongoing trial, MelMarT-II, has been designed with the aim of achieving a definitive answer to guide this fundamental surgical decision.
手术广泛局部切除(WLE)仍然是原发性皮肤黑色素瘤当前的标准治疗方法。WLE是一种选择性手术,旨在以最小的功能和美容损害实现局部区域疾病控制。尽管进行了多项前瞻性随机试验,但切除边缘的最佳范围仍存在争议,这在全球指南中一直缺乏共识中得到体现。此外,在黑色素瘤管理中手术作用不断演变的背景下,解读现有试验数据现在又增加了难度,随着我们对临床病理和基因组预后标志物的深入了解,前哨淋巴结活检(SNB)除了作为高危疾病辅助全身治疗的发展外,还经常作为分期程序常规使用。一项正在进行的试验MelMarT-II旨在为指导这一基本手术决策提供明确答案。